# Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

> **NCT02244242** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 493 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** Tamsulosin hydrochloride

## Key facts

- **NCT ID:** NCT02244242
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** 1999-08
- **Final completion:** —
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244242, "Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02244242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*